Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Orelabrutinib

    Client Email Product

    Orelabrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    25
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
    InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib

    https://www.businesswire.com/news/home/20240312903691/en

    BUSINESSWIRE
    12 Mar 2024
    Share Share
    InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
    InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib

    https://www.businesswire.com/news/home/20231026397005/en

    BUSINESSWIRE
    26 Oct 2023
    Share Share
    Study Result of Orelabrutinib in Patients with r/r MZL Published
    Study Result of Orelabrutinib in Patients with r/r MZL Published

    https://www.businesswire.com/news/home/20230912051988/en

    BUSINESSWIRE
    12 Sep 2023
    Share Share
    Latest Data of InnoCare's Orelabrutinib Presented at the 17th (ICML)
    Latest Data of InnoCare's Orelabrutinib Presented at the 17th (ICML)

    https://www.businesswire.com/news/home/20230615639879/en

    BUSINESSWIRE
    15 Jun 2023
    Share Share
    Clinical Study Result of Orelabrutinib in Patients with R/R MCL
    Clinical Study Result of Orelabrutinib in Patients with R/R MCL

    https://www.businesswire.com/news/home/20230501005058/en

    BUSINESSWIRE
    01 May 2023
    Share Share
    Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue
    Biogen CEO says company 'lost its way,' cuts $125M MS partnership amid declining revenue

    https://endpts.com/biogen-ceo-says-company-lost-its-way-cuts-125m-ms-partnership-amid-declining-revenue/

    Katherine Lewin ENDPTS
    16 Feb 2023
    Share Share
    Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published
    Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published

    https://www.businesswire.com/news/home/20230206005374/en

    BUSINESSWIRE
    06 Feb 2023
    Share Share
    China’s CDE grants approval for InnoCare’s NHL therapy trial
    China’s CDE grants approval for InnoCare’s NHL therapy trial

    https://www.clinicaltrialsarena.com/news/china-cde-innocare-nhl-therapy/

    CLINICALTRIALSARENA
    21 Dec 2022
    Share Share
    InnoCare Announces Approval to Conduct a Ph II Clinical Trial of Orelabrutinib
    InnoCare Announces Approval to Conduct a Ph II Clinical Trial of Orelabrutinib

    https://www.businesswire.com/news/home/20221220005453/en

    BUSINESSWIRE
    20 Dec 2022
    Share Share
    InnoCare Announces Approval of HIBRUKA (Orelabrutinib)
    InnoCare Announces Approval of HIBRUKA (Orelabrutinib)

    https://www.businesswire.com/news/home/20221121005992/en

    BUSINESSWIRE
    22 Nov 2022
    Share Share
    InnoCare Releases 2022 Third Quarter Results
    InnoCare Releases 2022 Third Quarter Results

    https://www.businesswire.com/news/home/20221113005085/en

    BUSINESSWIRE
    14 Nov 2022
    Share Share
    10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
    10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH

    https://www.businesswire.com/news/home/20221107005648/en

    BUSINESSWIRE
    07 Nov 2022
    Share Share
    China NMPA grants priority review for InnoCare’s orelabrutinib for lymphoma
    China NMPA grants priority review for InnoCare’s orelabrutinib for lymphoma

    https://www.pharmaceutical-technology.com/news/nmpa-priority-review-innocare-orelabrutinib/

    PHARMACEUTICAL-TECHNOLOGY
    06 Sep 2022
    Share Share
    InnoCare Announces Acceptance of Supplemental NDA for Orelabrutinib
    InnoCare Announces Acceptance of Supplemental NDA for Orelabrutinib

    https://www.businesswire.com/news/home/20220812005073/en

    BUSINESSWIRE
    12 Aug 2022
    Share Share
    Latest Data of InnoCare’s Orelabrutinib for SLE at LBA Session of EULAR 2022
    Latest Data of InnoCare’s Orelabrutinib for SLE at LBA Session of EULAR 2022

    https://www.businesswire.com/news/home/20220605005051/en

    BUSINESSWIRE
    05 Jun 2022
    Share Share
    InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib
    InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib

    https://www.prnewswire.com/news-releases/innocare-announces-approval-of-phase-ii-clinical-trial-using-orelabrutinib-for-the-treatment-of-nmosd-in-china-301493507.html

    PRNEWSWIRE
    01 Mar 2022
    Share Share
    InnoCare Begins Dosing in Phase II Clinical Trial Using Orelabrutinib for ITP
    InnoCare Begins Dosing in Phase II Clinical Trial Using Orelabrutinib for ITP

    https://www.prnewswire.com/news-releases/innocare-announces-dosing-of-first-patient-in-phase-ii-clinical-trial-using-orelabrutinib-for-the-treatment-of-itp-301487235.html

    PRNEWSWIRE
    22 Feb 2022
    Share Share
    InnoCare to Present Orelabrutinib Data atthe Upcoming 63rd Annual Meeting of ASH
    InnoCare to Present Orelabrutinib Data atthe Upcoming 63rd Annual Meeting of ASH

    https://www.prnewswire.com/news-releases/innocare-to-present-orelabrutinib-data-at-the-upcoming-63rd-annual-meeting-of-ash-301419300.html

    PRNEWSWIRE
    09 Nov 2021
    Share Share
    Biogen taps Chinese biotech InnoCare in $125M MS drug pact
    Biogen taps Chinese biotech InnoCare in $125M MS drug pact

    https://www.fiercebiotech.com/biotech/biogen-taps-chinese-biotech-innocare-125m-midstage-ms-drug-pact

    Ben Adams FIERCEBIOTECH
    14 Jul 2021
    Share Share
    InnoCare Presents Latest Clinical Data of Orelabrutinib at Conference
    InnoCare Presents Latest Clinical Data of Orelabrutinib at Conference

    https://www.prnewswire.com/news-releases/innocare-presents-latest-clinical-data-of-orelabrutinib-at-the16th-international-conference-on-malignant-lymphoma-301315342.html

    PRNEWSWIRE
    18 Jun 2021
    Share Share
    WuXi STA Supports Approval from NMPA for Orelabrutinib from InnoCare
    WuXi STA Supports Approval from NMPA for Orelabrutinib from InnoCare

    https://www.pharmtech.com/view/wuxi-sta-supports-approval-from-nmpa-for-orelabrutinib-from-innocare

    PHARMTECH
    11 Jan 2021
    Share Share
    China NMPA approves InnoCare’s orelabrutinib to treat patients with y CLL/ SLL
    China NMPA approves InnoCare’s orelabrutinib to treat patients with y CLL/ SLL

    http://www.pharmabiz.com/NewsDetails.aspx?aid=134419&sid=2

    PHARMABIZ
    28 Dec 2020
    Share Share
    InnoCare Announces the Approval of Orelabrutinib in China for Patients with
    InnoCare Announces the Approval of Orelabrutinib in China for Patients with

    https://www.businesswire.com/news/home/20201227005017/en

    BUSINESSWIRE
    28 Dec 2020
    Share Share
    China NMPA approves InnoCare’s orelabrutinib to treat patients with y CLL/ SLL
    China NMPA approves InnoCare’s orelabrutinib to treat patients with y CLL/ SLL

    http://www.pharmabiz.com/NewsDetails.aspx?aid=134419&sid=2

    PHARMABIZ
    28 Dec 2020
    Share Share
    InnoCare Announces the Approval of Orelabrutinib in China for Patients with
    InnoCare Announces the Approval of Orelabrutinib in China for Patients with

    https://www.businesswire.com/news/home/20201227005017/en

    BUSINESSWIRE
    28 Dec 2020
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search